00:09:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-08-21 Extra Bolagsstämma 2023
2024-06-20 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ASAP 0.00 SEK
2024-02-27 Bokslutskommuniké 2023
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-23 X-dag ordinarie utdelning ASAP 0.00 SEK
2023-05-22 Årsstämma 2023
2023-02-27 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 X-dag ordinarie utdelning ASAP 0.00 SEK
2022-05-04 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 15-10 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-18 Kvartalsrapport 2021-Q1
2021-04-22 X-dag ordinarie utdelning ASAP 0.00 SEK
2021-04-21 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-26 Kvartalsrapport 2020-Q1
2020-05-06 X-dag ordinarie utdelning ASAP 0.00 SEK
2020-05-05 Årsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2020-01-21 Extra Bolagsstämma 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-20 Kvartalsrapport 2019-Q1
2019-05-09 X-dag ordinarie utdelning ASAP 0.00 SEK
2019-02-25 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Asarina Pharma är ett svenskt läkemedelsbolag med fokus på läkemedel för kvinnors hälsa. Bolagets huvudprodukt, som är under utveckling, är Sepranolone. Sepranolone är avsett för behandling av PMDD, den allvarligaste formen av Premenstruel stress (PMS). Verksamhet innehas runtom den nordiska marknaden. Asarina Pharma har sitt huvudkontor i Solna, Sverige.
2024-06-27 11:33:00

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (the “Company”) on 27 June 2024 at Fredersen Advokatbyrå's premises at Birger Jarlsgatan 8, Stockholm.

Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the Managing Director were discharged from liability for the financial year 2023.

Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2023 and that the results of the company shall be carried forward.

Board of Directors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Paul de Potocki, Erin Gainer and Marianne Kock as board members. Paul de Potocki was re-elected as the Chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young Aktiebolag as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the Nomination Committee’s proposal. The Board members proposed for re-election declared their willingness to waive their respective remuneration until the Company has received financing and/or entered into partnerships that enable payment thereof. The AGM furthermore resolved in accordance with the Nomination Committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination Committee for the next Annual General Meeting
The AGM resolved, in accordance with the Nomination Committee’s proposal, that the principles for the appointment of the Nomination Committee adopted at the AGM 2020 shall continue to apply also for the appointment of the Nomination Committee ahead of the AGM 2025.